AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum

Traders Union
All News
Stocks
AstraZeneca jumps 3.24% on AI drug deal

Highlights

AstraZeneca entered a strategic agreement with insitro to use AI for drug discovery targeting liver and heart diseases.
The partnership expands AstraZeneca research into high unmet-need therapeutic areas and integrates advanced AI technology into its pipeline.
Shares of AstraZeneca gained 3.24% to GBX12,698, with technical indicators supporting further upside within a projected GBX12,255 to GBX13,140 range.

AI-driven partnership with insitro boosts sentiment amid drug discovery push

AstraZeneca has announced a strategic drug discovery and licensing agreement with insitro, an AI-driven drug discovery company, to identify potential treatments for liver and heart diseases, according to Stocktwits. This partnership extends AstraZeneca's research capabilities and brings cutting-edge AI technology into its portfolio, signaling expansion in therapeutic areas with significant unmet needs. The move is likely to boost sentiment and attract further market interest as investors assess the potential for new high-value treatments emerging from this collaboration.

Bullish momentum confirmed as overbought signals warn of stretched rally

On the technical front, AZN is trading above its MA-20 at GBX12,284 and the MA-50 at GBX12,152 on the hourly chart, while remaining below the long-term MA-200 at GBX13,493 on the daily chart. The Ichimoku Kijun level at GBX12,310 provides immediate support. Momentum indicators are consistently bullish: MACD, ADX, and Awesome Oscillator all confirm strong intraday buying, with Bull/Bear Power also indicating clear buyer dominance. However, RSI at 76.32 as well as Stoch RSI and CCI signal overbought conditions, highlighting stretched short-term sentiment amid robust upward momentum.

Consolidation likely as higher volatility frames breakout and reversal risks

In the short term, price action for AZN is expected to consolidate within a volatility band of GBX12,255 to GBX13,140. Upward continuation has a high probability, with current data suggesting a 75% chance of further gains if resistance levels are breached. Conversely, a reversal becomes more likely if the stock falls below the GBX12,310 support, setting the stage for a potential pullback.

Viktoras Karapetjanc, Traders Union expert, views AstraZeneca’s latest collaboration with insitro as a strong catalyst for renewed investor confidence. He believes the integration of advanced AI-driven drug discovery positions the company for expanded long-term growth potential, especially in high-demand therapeutic areas. With technical momentum supporting the move and positive sentiment building, Karapetjanc sees further gains likely if the stock stays above key support levels. "This partnership marks a bold strategic step and, if momentum persists above GBX12,310, I expect continued upside for AZN in the near term."

Previously it was reported that AstraZeneca entered into a significant AI-driven drug discovery partnership with insitro to target challenging liver and heart diseases. The current technical setup, with momentum indicators remaining bullish despite overbought signals, highlights GBX12,310 as a critical support level for traders monitoring the next directional move.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.